DOCSLIB.ORG

20151122 NIS Protocol Template Including PASS

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
20151122 NIS Protocol Template Including PASS 1RQ,QWHUYHQWLRQDO6WXG\3URWRFRO 6WXG\3URWRFRO1XPEHU 06B 7LWOH $QRQLQWHUYHQWLRQDOUHJLVWHUEDVHGFRPSDUDWLYHHIIHFWLYHQHVVVWXG\RI UK)6+DOIDUHIHUHQFHSURGXFWYVKLJKO\SXULILHGKXPDQPHQRSDXVDO JRQDGRWURSLQRUUK)6+DOIDELRVLPLODUSURGXFWVIRURYDULDQVWLPXODWLRQ LQLQYLWURIHUWLOL]DWLRQRULQWUDF\WRSODVPLFVSHUPLQMHFWLRQWUHDWPHQWLQ 'HQPDUNDQG6ZHGHQ±7KH1RUGLF)ROOLWURSLQ$OID&RPSDUDWLYH (IIHFWLYHQHVV 125')$&( 6WXG\ 3URWRFROYHUVLRQLGHQWLILHU 3URWRFRO'DWH9HUVLRQ 0D\9HUVLRQ 5HSODFHV9HUVLRQ 0D\9HUVLRQ (83$6UHJLVWHUQXPEHU 6WXG\QRW\HWUHJLVWHUHG WREHUHJLVWHUHGLQ(83$6UHJLVWHU $FWLYHVXEVWDQFH **$)ROOLWURSLQDOID **$+XPDQPHQRSDXVDOJRQDGRWURSLQ 0HGLFLQDOSURGXFW )ROOLWURSLQ DOID UHFRPELQDQW KXPDQ IROOLFOHVWLPXODWLQJ KRUPRQH UK)6+ +XPDQPHQRSDXVDOJRQDGRWURSLQ 6SRQVRU 0HUFN+HDOWKFDUH.*D$ DQDIILOLDWHRI0HUFN.*D$'DUPVWDGW*HUPDQ\ )UDQNIXUWHU6WU 'DUPVWDGW*HUPDQ\ 5HVHDUFKTXHVWLRQDQG 7KH UHVHDUFK TXHVWLRQ LV ZKHWKHU DPRQJ ZRPHQ XQGHUJRLQJ LQ YLWUR REMHFWLYHV IHUWLOL]DWLRQ ,9) RULQWUDF\WRSODVPLFVSHUPLQMHFWLRQ ,&6, WUHDWPHQW UHFRPELQDQWKXPDQIROOLFOHVWLPXODWLQJKRUPRQH UK)6+ DOIDUHIHUHQFH SURGXFW LV DVVRFLDWHG ZLWK EHWWHU WUHDWPHQW UHVXOWV WKDQ KLJKO\ SXULILHG KXPDQ PHQRSDXVDO JRQDGRWURSLQ +3K0* RU UK)6+DOID ELRVLPLODU SURGXFWVLQWHUPVRIFOLQLFDOHIIHFWLYHQHVVDQGVDIHW\RXWFRPHV 3ULPDU\2EMHFWLYH 7KHSULPDU\REMHFWLYHRIWKLVVWXG\LVWRFRPSDUHUK)6+DOIDUHIHUHQFH SURGXFWZLWK+3K0*RUUK)6+DOIDELRVLPLODUSURGXFWVUHJDUGLQJWKH IROORZLQJOLYHELUWKRXWFRPHV D /LYHELUWKUDWHSHULQLWLDWHG,9),&6,VWLPXODWLRQF\FOH E &XPXODWLYHOLYHELUWKUDWHSHULQLWLDWHG,9),&6,VWLPXODWLRQ F\FOH F &XPXODWLYHOLYHELUWKUDWHLQXSWRILYHLQLWLDWHG,9),&6, VWLPXODWLRQF\FOHV 6HFRQGDU\2EMHFWLYHV 7RFRPSDUHUK)6+DOIDUHIHUHQFHSURGXFWZLWK+3K0*RUUK)6+DOID ELRVLPLODUSURGXFWVUHJDUGLQJWKHIROORZLQJRXWFRPHV D &OLQLFDO SUHJQDQF\ UDWH DQG RQJRLQJ SUHJQDQF\ UDWH SHU LQLWLDWHG,9),&6,VWLPXODWLRQF\FOHDQGE &XPXODWLYHFOLQLFDO SUHJQDQF\ UDWH DQG FXPXODWLYH RQJRLQJ SUHJQDQF\ UDWH SHU LQLWLDWHG,9),&6,VWLPXODWLRQF\FOH 1XPEHU RI RRF\WHV UHWULHYHG HPEU\RV WUDQVIHUUHG HPEU\RV FU\RSUHVHUYHG DQG XWLOL]DEOH HPEU\RV SHU LQLWLDWHG ,9),&6, VWLPXODWLRQF\FOHDQGSHURRF\WHUHWULHYDOF\FOH ,PSODQWDWLRQUDWH 7LPHWROLYHELUWKLQXSWRILYH,9),&6,VWLPXODWLRQF\FOHV 5DWHRISUHJQDQF\ORVVIRUWKHILUVW DQGVXFFHVVLYH ,9),&6, VWLPXODWLRQF\FOH V 5DWH RI PXOWLSOH SUHJQDQF\ IRU WKH ILUVW DQG VXFFHVVLYH ,9),&6,VWLPXODWLRQF\FOH V 1XPEHU RI FDQFHOOHG F\FOHV IRU WKH ILUVW DQG VXFFHVVLYH ,9),&6,VWLPXODWLRQF\FOH V 1XPEHURIRYDULDQK\SHUVWLPXODWLRQV\QGURPHFDVHVIRUWKHILUVW DQGVXFFHVVLYH ,9),&6,VWLPXODWLRQF\FOH V $Q DGGLWLRQDO VHFRQGDU\ REMHFWLYH GHVFULEHV FRVWV DVVRFLDWHG ZLWK WKH UK)6+DOID UHIHUHQFH SURGXFW +3K0* DQG UK)6+DOID ELRVLPLODU SURGXFWVLQGLYLGXDOO\DQGRYHUDOODFURVVDOOSURGXFWV &RVWVDVVRFLDWHGZLWK,9),&6,WUHDWPHQW LQFOXGLQJGUXJVDQG RWKHU WUHDWPHQWV PLVFDUULDJHELUWK DQG DGYHUVH HYHQWV LH 2+66 &RXQWULHVRIVWXG\ 'HQPDUN 6ZHGHQ $XWKRU 33' 7KLVGRFXPHQWLVWKHSURSHUW\RI0HUFN.*D$'DUPVWDGW*HUPDQ\RURQHRILWVVXEVLGLDULHV,WLVLQWHQGHGIRU UHVWULFWHGXVHRQO\DQGPD\QRW±LQIXOORUSDUW±EHSDVVHGRQUHSURGXFHGSXEOLVKHGRUXVHGZLWKRXWH[SUHVV SHUPLVVLRQRI0HUFN.*D$'DUPVWDGW*HUPDQ\RULWVVXEVLGLDU\ &RS\ULJKW E\ 0HUFN .*D$ 'DUPVWDGW *HUPDQ\ RU LWV VXEVLGLDU\ $OOULJKWVUHVHUYHG 1 Table of Contents 1 Table of Contents ..................................................................................3 2 List of Abbreviations ............................................................................6 3 Responsible Parties ...............................................................................9 4 Abstract ...............................................................................................11 5 Amendments and Updates ..................................................................18 6 Milestones ...........................................................................................18 7 Rationale and Background ..................................................................19 8 Research Question and Objectives .....................................................22 8.1 Primary Objective ...............................................................................22 8.2 Secondary Objectives .........................................................................22 9 Research Method ................................................................................23 9.1 Study Design .......................................................................................23 9.1.1 Design Overview ................................................................................23 9.1.2 Outcomes ............................................................................................25 9.2 Setting .................................................................................................29 9.2.1 Study Population .................................................................................29 9.2.2 Definition of Study Cohorts and Description of Treatments ..............30 9.2.3 Study Time Periods .............................................................................31 9.3 Variables .............................................................................................32 9.3.1 Exposure Variables .............................................................................32 9.3.2 Other Variables (Covariates) ..............................................................33 9.4 Data Source .........................................................................................36 9.4.1 Denmark .............................................................................................37 9.4.2 Sweden ................................................................................................39 9.5 Study Size ...........................................................................................40 9.6 Data Management ...............................................................................46 9.7 Data Analysis ......................................................................................46 9.7.1 Analysis Sets .......................................................................................47 9.7.2 Derived and Transformed Data ..........................................................51 9.7.3 Statistical Methods ..............................................................................51 9.7.4 Sequence of Analyses .........................................................................66 3/100 9.8 Quality Control ...................................................................................66 9.9 Limitations of the Research Methods .................................................67 9.9.1 Selection Bias .....................................................................................67 9.9.2 Information Bias .................................................................................67 9.9.3 Confounding by Baseline Characteristics ...........................................69 9.9.4 Unmeasured Confounding ..................................................................69 9.9.5 Study Size and Time Trends ...............................................................70 9.9.6 Generalizability ...................................................................................70 9.10 Other Aspects ......................................................................................70 9.10.1 Independent Ethics Committee or Institutional Review Board ..........70 9.10.2 Quality Assurance ...............................................................................71 9.10.3 Archiving ............................................................................................71 10 Protection of Human Subjects ............................................................71 10.1 Subject Identification and Privacy ......................................................71 11 Management and Reporting of Adverse Events .................................71 12 Plans for Disseminating and Communicating Study Results .............72 12.1 Study Report .......................................................................................72 12.2 Publication ..........................................................................................72 12.3 Cost Results in Health-Economic Studies ..........................................72 13 References ...........................................................................................73 14 Appendices .........................................................................................79 14.1 List of Stand-Alone Documents .........................................................79 14.2 ENCePP Checklist for Study Protocols ..............................................80 14.3 Additional Information .......................................................................86 14.3.1 Outcome variables (Section 9.1.2): Diagnosis and Procedure Codes for Definition and Databases for Identification .......................86 14.3.2 Censoring Criteria (Section 9.2.3): Diagnosis and Procedure Codes for Definition ...........................................................................89 14.3.3 Exposure (Section 9.3.1) and Other Variables (Section 9.3.2): Codes for Definition ...........................................................................90 14.3.4 Summary of the Cost-effectiveness Model .........................................94 14.4 Signature Pages and Responsible Persons for the Study ....................95 Signature Page – Protocol Lead .........................................................................................96 4/100 Signature Page – Principal-in-Charge, Coordinating
Load more

Recommended publications
  • HISO 10030.2 Electronic Pharmaceutical Messaging Standard
    Electronic Pharmaceutical Messaging Standard HISO 10030.2 To be used in conjunction with HISO 10030.1 Electronic Pharmaceutical Business Processes Standard Copyright information This document has been approved as a standard for the New Zealand health and disability sector by the Health Information Standards Organisation (HISO), a sub-committee of HISAC. The copyright owner of this document is the Health Information Strategy Action Committee (HISAC), which is a ministerial committee appointed by the Minister of Health. HISO work on this document may be reproduced in any number of copies and in any format or medium provided: • the content is not changed; • the material is not sold; • the material is not used to promote or endorse any product or service; • the material is not used in an inappropriate or a misleading context having regard to the nature of the material; • any disclaimers included on the published information are reproduced on the material; • a copyright acknowledgment to the Health Information Strategy Action Committee is included. Permission to reproduce HISAC work does not extend to include any work identified in this document as the copyright material of a party other than HISAC. Authorisation to reproduce such material must be obtained from the copyright holders concerned. Published in November 2008 by HISAC PO Box 5013, Wellington, New Zealand ISBN 978-0-478-31780-0 (Online) This document is available on the HISAC website: http://www.hisac.govt.nz Electronic Pharmaceutical Messaging Standard v1 November 2008 2 Contents
    [Show full text]
  • Member of the Year
    May 2011 2010 Member of the Year Maryann Palmeter, CPC, CENTC Plus: 2011-2013 NAB • Modifier 33 • Template Caution • May MAYnia • Neurostimulation MLN CodingEdge Ad 5.2011 FINAL PRINT.pdf 1 3/9/11 12:29 PM R C M Y CM MY CY CMY K Contents 14 22 47 May 2011 [contents] In Every Issue 7 Letter from the President and CEO 8 Coding News 11 Letter from Member Leadership 12 Letters to the Editor 25 Kudos 42 Special Features Features Online Test Yourself – Earn 1 CEU 16 Modifier 33 Arrives Quietly But Packs a Punch go to www.aapc.com/resources/ Brad Ericson, MPC, CPC, COSC publications/coding-edge/archive.aspx 18 Use Templates with Caution 30 Welcome 2011-2013 NAB Peggy Stilley, CPC, CPMA, CPC-I, COBGC, ACS-OB 39 Audit Team Finds Paradise 22 Next Step in ED Leveling: Evaluation Methodologies Jim Strafford, CEDC, MCS-P 50 Minute with a Member 26 Educate Yourself on Proper E/M Caral Edelberg, CPC, CPMA, CAC, CCS-P, CHC Education 28 Maryann Palmeter: Coding, Compliance, and Cows 14 Ideas to Bring Your Chapter to Life Michelle A. Dick 38 Newly Credentialed Members 42 Append 22 to Unusually Difficult Procedures Sarah Reed, CPC, and G.J. Verhovshek, MA, CPC Coming Up 44 Learn What’s New for Neurostimulation G.J. Verhovshek, MA, CPC • Chapter of the Year • New AAPCCA 47 It’s Here: Rampant Health Care Fraud and Abuse Lynn Berry, PT, CPC • Interstitial Device Placement On the Cover: AAPC’s 2010 Member of the Year, Maryann C. Palmeter, CPC, CENTC, • Bundling Basics director of physician billing compliance at University of Florida Jacksonville Healthcare, Inc., found that the secret to happiness is the three Cs: coding, compliance, and cows.
    [Show full text]
  • Inleiding Meddra Versie 21.1
    Inleiding MedDRA versie 21.1 September 2018 000225 Kennisgeving aan de lezer Kennisgeving aan de lezer Deze Inleiding is in het Nederlands geschreven en dient uitsluitend voor gebruik met de Nederlandse versie van MedDRA. Er zijn aanvullende inleidingen ontwikkeld ter ondersteuning van andere talen dan het Engels. Deze dienen in vertaling te worden meegeleverd. De Inleiding dient voor gebruik in combinatie met de MedDRA Browsers, die verkrijgbaar zijn bij elk MedDRA-abonnement. Versiespecifieke wijzigingen of wijzigingen in de documentatie zijn te vinden in het document ‘Wat is nieuw'. Dit document is opgenomen met de MedDRA-versie, en is ook op de MSSO-website geplaatst in het gedeelte met ondersteunende documentatie. De MedDRA-terminologie wordt gehandhaafd onder een ISO 9001:2015 gedeponeerd kwaliteitsbeheersysteem. Er zijn geen wijzigingen van belang in de MedDRA-inleiding versie 21.1. Inleiding MedDRA versie 21.1 ii September 2018 000225 Dankbetuiging Dankbetuiging Het MedDRA®-handelsmerk is door IFPMA gedeponeerd namens de ICH. Ook worden de volgende informatiebronnen erkend: Diagnostical and Statistical Manual of Mental Disorders, vijfde editie (DSM-5) Copyright 2013 American Psychiatric Association. ICD-9-CM, International Classification of Diseases, negende druk, Clinical Modification, Copyright 1998 Medicode, Inc. COSTART Thesaurus vijfde druk, Copyright 1995 US Food and Drug Administration (FDA). Hoechst Adverse Reaction Terminology System (HARTS), Copyright 1992 Aventis Pharma. WHO Adverse Reaction Terminology (WHO-ART), Copyright 1998 World Health Organization Collaborating Centre for International Drug Monitoring. Japanese Adverse Reaction Terminology (J-ART) is een product van de Ministry of Health, Labour and Welfare (MHLW). LOINC is een gedeponeerd handelsmerk van Regenstrief Institute, Inc. Lanoxin is een gedeponeerd handelsmerk van GlaxoSmithKline.
    [Show full text]
  • HISO 10030.1 Electronic Pharmaceutical
    Electronic Pharmaceutical Business Process Standard HISO 10030.1 To be used in conjunction with HISO 10030.2 Electronic Pharmaceutical Messaging Standard Copyright Information This document has been approved as a Standard for the New Zealand health and disability sector by the Health Information Standards Organisation (HISO), a sub-committee of the Health Information Strategy Action Committee (HISAC), which is a ministerial committee appointed by the Minister of Health. HISAC is the copyright owner of this document. HISO work on this document may be reproduced in any number of copies and in any format or medium provided: • the content is not changed; • the material is not sold; • the material is not used to promote or endorse any product or service; • the material is not used in an inappropriate or a misleading context having regard to the nature of the material; • any disclaimers included on the published information are reproduced on the material; • a copyright acknowledgment to the Health Information Strategy Action Committee is included. Permission to reproduce HISAC work does not extend to include any work identified in this document as the copyright material of a party other than HISAC. Authorisation to reproduce such material must be obtained from the copyright holders concerned. Published in October 2008 by HISAC PO Box 5013, Wellington, New Zealand ISBN 978-0-478-31777-0 (Online) This document is available on the HISAC website: http://www.hisac.govt.nz EPharmaceutical Business Process v1 Page 2 of 57 October 2008 Contents 1 Introduction
    [Show full text]
  • Developing a Coding Compliance Program 5
    C HAPTER Developing a Coding Compliance Program 5 Objectives At the completion of this chapter, the learner should be able to: • Identify the seven key components of a corporate compliance program. • Describe the importance of a corporate compliance program and the purpose of a coding compliance program. • Discuss the purpose of the Offi ce of Inspector General’s compliance guidance for health care entities and identify key elements. • Describe the difference between “mandatory” and “permissive” offenses. • Discuss the roles of the coding compliance manager and the coding compliance committee. • Identify areas that should be defi ned within coding compliance policies. • Discuss the importance of coding compliance education. • Recognize the importance of coding accuracy and distinguish between coding and documentation errors. • Explain differences in coding certifi cation and professional coding organizations. • Identify the coding resources that must be kept up to date. Key Terms chargemaster coding resources mandatory exclusions Recovery Audit code of conduct compliance offi cer OIG Compliance Contractors (RACs) coding certifi cation compliance program Guidance structure coding compliance Comprehensive Error outcomes coding compliance Rate Testing (CERT) outcome indicators education program permissive exclusions Coding Compliance corporate compliance process Manager program 2009 Current Procedural Terminology © 2008 American Medical Association. All Rights Reserved. 3921X_05_ch05_p093-118.indd 93 9/29/09 2:40:45 PM 94 Chapter 5 Developing a Coding Compliance Program Integrating Coding and Corporate Compliance Corporate businesses and health care organizations alike may be subject to criminal and civil actions under a variety of federal and state laws, including the False Claims Act, the Wire and Mail Fraud Act, securities and employment laws, and a number of others.
    [Show full text]
  • How Different Databases Shape Epidemiological Research Questions 2020
    The elderly, the young, and the ill: How different databases shape epidemiological research questions Inauguraldissertation zur Erlangung der Würde eines Doktors der Philosophie vorgelegt der Philosophisch-Naturwissenschaftlichen Fakultät der Universität Basel von Rahel Schneider 2020 Originaldokument gespeichert auf dem Dokumentenserver der Universität Basel edoc.unibas.ch Genehmigt von der Philosophisch-Naturwissenschaftlichen Fakultät Auf Antrag von Prof. Dr. Christoph R. Meier Prof. Dr. Kurt E. Hersberger Prof. Dr. David Schwappach Basel, den 26. Mai 2020 Prof. Dr. Martin Spiess Dekan Inference - Sämy Steiger, Swiss artist and architect « Words are, in my not-so-humble opinion, our most inexhaustible source of magic. Capable of both inflicting injury, and remedying it. » Dumbledore - Harry Potter and the Deathly Hallows Acknowledgements The work presented in this thesis was conducted between December 2016 and May 2020 at the Basel Pharmacoepidemiology Unit at the Institute for Clinical Pharmacy and Epidemiology of the University of Basel. ‘It takes a village to raise a child’ is an African proverb that says it needs an entire community of people to interact with children for them to experience and grow in a safe and healthy environment. In my case, it has indeed taken a village. Not to raise me as a child, but to raise me as an epidemiologist. The support, assistance, and trust of the people mentioned in this chapter was of immeasurable value for the successful outcome of this project, and fills my heart with gratitude. First and foremost, my special thank goes to Prof. Dr. Christoph Meier, without whom this thesis would not have been possible. Thank you, Christoph, for your unlimited trust and kindness, and for sharing your brilliant expertise of pharmacoepidemiology with me.
    [Show full text]
  • Non-Interventional (Ni) Study Protocol Pass
    XALKORI (crizotinib) A8081038, A Multinational Active Safety Surveillance Study of Crizotinib in Europe Final Protocol Amendment 2, 19 Febuary 2015 NON-INTERVENTIONAL (NI) STUDY PROTOCOL PASS Information Title A multinational active safety surveillance study of crizotinib in Europe and the United States Protocol number A8081038 Protocol version identifier Final (version 1.2) Date of last version of protocol 19 Febuary 2015 EU Post Authorisation Study (PAS) ENCEPP/SDPP/8097 register number Active substance L01XE16/Crizotinib Medicinal product XALKORI Product reference EU/1/12/793/001-004 Product number EMEA/H/C/002489 Marketing Authorisation Holder (MAH) Pfizer Limited Joint PASS No Research question and objectives The objective of this study is to evaluate the safety and effectiveness of crizotinib among lung cancer patients in the real world setting in Europe and the United States. Countries of study Denmark, Finland, Sweden, the Netherlands and the United States Author Kui Huang, PhD, MPH Pfizer Inc 235 East 42nd Street New York, NY 10017 090177e18627024f\Approved\Approved On: 25-Feb-2015 14:49 Pfizer Confidential Page 1 of 63 XALKORI (crizotinib) A8081038, A Multinational Active Safety Surveillance Study of Crizotinib in Europe Final Protocol Amendment 2, 19 Febuary 2015 Marketing Authorisation Holder(s) Marketing Authorisation Holder(s) Pfizer Limited Ramsgate Road, Sandwich, Kent CT130NJ United Kingdom MAH contact person Kui Huang, PhD, MPH Pfizer Inc 235 East 42nd Street New York, NY 10017 This document contains confidential information belonging to Pfizer. Except as otherwise agreed to in writing, by accepting or reviewing this document, you agree to hold this information in confidence and not copy or disclose it to others (except where required by applicable law) or use it for unauthorized purposes.
    [Show full text]
  • Zoledronic Acid (Zometa® & Reclast®)
    Reimbursement Policy Zoledronic Acid (Zometa® & Reclast®) Policy ZOL07012013RP Approved UnitedHealthcare Medicare Current 08/27/2014 Number By Reimbursement Policy Committee Approval Date IMPORTANT NOTE ABOUT THIS REIMBURSEMENT POLICY This policy is applicable to UnitedHealthcare Medicare Advantage Plans offered by UnitedHealthcare and its affiliates. You are responsible for submission of accurate claims. This reimbursement policy is intended to ensure that you are reimbursed based on the code or codes that correctly describe the health care services provided. UnitedHealthcare reimbursement policies use Current Procedural Terminology (CPT®*), Centers for Medicare and Medicaid Services (CMS), or other coding guidelines. References to CPT or other sources are for definitional purposes only and do not imply any right to reimbursement. This reimbursement policy applies to all health care services billed on CMS 1500 forms and, when specified, to those billed on UB04 forms (CMS 1450). Coding methodology, industry-standard reimbursement logic, regulatory requirements, benefits design and other factors are considered in developing reimbursement policy. This information is intended to serve only as a general resource regarding UnitedHealthcare’s reimbursement policy for the services described and is not intended to address every aspect of a reimbursement situation. Accordingly, UnitedHealthcare may use reasonable discretion in interpreting and applying this policy to health care services provided in a particular case. Further, the policy d006Fes not address all issues related to reimbursement for health care services provided to UnitedHealthcare enrollees. Other factors affecting reimbursement may supplement, modify or, in some cases, supersede this policy. These factors may include, but are not limited to: legislative mandates, the physician or other provider contracts, and/or the enrollee’s benefit coverage documents.
    [Show full text]
  • Wikidata: a Large-Scale Collaborative Ontological Medical Database
    Wikidata: A large-scale collaborative ontological medical database Houcemeddine Turki1, Thomas Shafee2, Mohamed Ali Hadj Taieb3, Mohamed Ben Aouicha4, Denny Vrandečid5, Diptanshu Das6, Helmi Hamdi7 1Faculty of Medicine of Sfax, University of Sfax, Sfax, Tunisia [email protected] 2La Trobe University, Bundoora, Melbourne, Victoria, Australia [email protected] 3,4Faculty of Sciences of Sfax, University of Sfax, Sfax, Tunisia [email protected] [email protected] 5Google LLC, Mountain View, California, United States of America [email protected] 6Institute of Neurosciences Kolkata (I-NK), Kolkata, India [email protected] 7CUFE, Université de Sherbrooke, Sherbrooke, Canada [email protected] Highlights: Wikidata is a flexible biomedical semantic knowledge-base It has the potential to perform a much better role as a large-scale biomedical semantic resource Tools are available to query, enrich, verify and process the biomedical knowledge Abstract: Created in October 2012, Wikidata is a large-scale, human-readable, machine-readable, multilingual, multidisciplinary, centralized, editable, structured, and linked knowledge-base with an increasing diversity of use cases. Here, we raise awareness of the potential use of Wikidata as a useful resource for biomedical data integration and semantic interoperability between biomedical computer systems. We show the data model and characteristics of Wikidata and explain how this database can be automatically processed by users as well as by
    [Show full text]
  • DRUG CONSUMPTION DATABASES in EUROPE Countries Summary
    WP2 Framework for pharmacoepidemiological studies WG3 Drug utilisation data DRUG CONSUMPTION DATABASES IN EUROPE Countries summary First version August 2011 Updated version November 2013 PROTECT Drug consumption databases in Europe – Countries summary PROTECT: Pharmacoepidemiological Research on Outcomes of Therapeutics by a European Consortium The PROTECT project is receiving funding from the European Community’s Seventh Framework Programme (FP7/2007-2013) for the Innovative Medicines Initiative (IMI). IMI Call topic: Call No.6: Strengthening the Monitoring of Benefit/Risk (Call Identifier: IMI_Call_2008_1_06). Grant agreement nº 115004. Page 2 of 70 PROTECT Drug consumption databases in Europe – Countries summary Working Package 2 (Working Group 3) participants and affiliation Name Institution Country Role in WP2 Joan-Ramon Laporte Luisa Ibáñez Mònica Sabaté Foundation Catalan Institute of Spain WG3 participants Elena Ballarín Pharmacology (FICF) Pili Ferrer Paula Solari1 Sam Yeboa2 Kay Lay Goh3 Amgen United Kingdom WG3 participants Marieke Shoonen4 Joan Fortuny Novartis Spain WG3 participants Joerg Hasford Ludwig Maximilians Universität Germany WG3 participants Marietta Rottenkolber (LMU) Olaf Klungel Utrecht University (UU) The Netherlands WP2 co-lead Hans Petri L.A. Hoffmann-Roche (Roche) United Kingdom Switzerland WG3 participants Iain Tatt5 Robert Reynolds Pfizer United States WP2 co-lead Participated during the first 18 months of the project 2 Participated during the first 20 months of the project 3 Participated during the first 21 months of the project 4 Participation from April 2012 5 Participation from April 2012 Document type: report Release date: December, 2012 Page 3 of 70 PROTECT Drug consumption databases in Europe – Countries summary WP2 Co-leaders: Olaf Klungel (UU) and Robert Reynolds (Pfizer).
    [Show full text]
  • Glossary Terms
    Commission for Case Manager Certification GLOSSARY of TERMS PUBLISHED BY THE COMMMISSION FOR CASE MANAGER CERTIFICATION (CCMC) WWW.CCMCERTIFICATION.ORG DISCLAIMER: The glossary of terms is a list of terms directly or indirectly related to the practice of case management compiled by members of CCMC’s Exam and Research Committee (ERC) and based on published literature related to case management. The list is not meant to be exhaustive. It is organized based on major aspects of case management practice. Each term is included in the category deemed most appropriate based on the judgment of ERC members. Please note that not every term will appear on the examination. CCMC suggests that candidates for the CCM exam be familiar with terms and concepts relevant to case management. This list should be helpful in that regard. TERM DEFINITION AAPM&R American Academy of Physical Medicine and Rehabilitation ACCESS TO CARE The ability and ease of clients to obtain healthcare when they need it. ACCESSIBLE A term used to denote building facilities that are barrier-free thus enabling all members of society safe access, including persons with physical disabilities. ACCOUNTABLE CARE A set of healthcare providers including primary care physicians, specialists, and ORGANIZATION (ACO) hospitals that work together collaboratively and accept collective accountability for the cost and quality of care delivered to a population of patients. ACOs became popular in the Medicare fee-for-service benefit system as a result of the Affordable Care Act. ACOs are formed around a variety of existing types of provider organizations such as multispecialty medical groups, physician-hospital organizations (PHO), and organized or integrated delivery systems (accountable care facts, available at http://www.accountablecarefacts.org/topten/what-is-an- accountable-care-organization-aco-1, accessed 2/16/2014).
    [Show full text]
  • State of the Art for Healthcare Ontology D407.010
    THE RESEARCH LEADING TO THESE RESULTS HAS RECEIVED FUNDING FROM THE EUROPEAN UNION’S SEVENTH FRAMEWORK PROGRAM (FP7/2007-2013) FOR CRYSTAL – CRITICAL SYSTEM ENGINEERING ACCELERATION JOINT UNDERTAKING UNDER GRANT AGREEMENT N° 332830 AND FROM SPECIFIC NATIONAL PROGRAMS AND / OR FUNDING AUTHORITIES. CRitical SYSTem Engineering AcceLeration State of the art for Healthcare ontology D407.010 State of the art for D407.010 Healthcare ontology DOCUMENT INFORMATION Project CRYSTAL Grant Agreement No. ARTEMIS-2012-1-332830 Deliverable Title State of the art for Healthcare ontology Deliverable No. D407.010 Dissemination Level PU Nature R Document Version V1.0 Date 2013-01-31 Contact M.A. van Bekkum Organization TNO Phone +31610968792 E-Mail [email protected] Version Nature Date Page V1.0 R 2014-01-31 2 of 54 State of the art for D407.010 Healthcare ontology AUTHORS TABLE Name Company E-Mail L. Oosterheert (lead editor) TNO [email protected] M.A. van Bekkum TNO [email protected] A.M. Farcasi TU/e [email protected] R. de Juan Marín ITI [email protected] E. Lluna ITI [email protected] R. Albers Philips [email protected] H.E.P. Cruts Philips [email protected] D. Segers Barco [email protected] T. van Velzen (external reviewer) IBM [email protected] T. Karbe (external reviewer) TU Berlin [email protected] CHANGE HISTORY Pages Version Date Reason for Change Affected 0.1 18-11-2013 Creation of Table of Contents (TNO) All Added preliminary content of chapters, first version of long 0.11 06-12-2013 7-13, Annex I list (TNO)
    [Show full text]